Skip to Main Content

Paper Details

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Oncotarget
50
2015
-, ATC, ATC cell lines, Anaplastic thyroid cancer, CUDC-101, E-cadherin, EGFR, HDAC, HDACs, HER2, MAPK, N-cadherin, Vimentin, XIAP, anaplastic thyroid cancer, caspase, catenin, histone, histone 3, histone deacetylase, human, malignancies, metastatic ATC, mouse, p21, survivin, tumor
Author NameAffiliation
Lisa ZhangNational Cancer Institute, National Institutes of Health
Lisa ZhangNational Cancer Institute, National Institutes of Health
Yaqin ZhangDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Yaqin ZhangDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Amit MehtaNational Cancer Institute, National Institutes of Health
Amit MehtaGeisel School of Medicine at Dartmouth
Amit MehtaNational Cancer Institute, National Institutes of Health
Amit MehtaGeisel School of Medicine at Dartmouth
Myriem BoufraqechNational Cancer Institute, National Institutes of Health
Myriem BoufraqechNational Cancer Institute, National Institutes of Health
Sean DavisCenter for Cancer Research, National Cancer Institute
Susan R DavisCenter for Cancer Research, National Cancer Institute
Jing WangCuris Inc.
Ze TianCuris Inc.
Zhiya YuNational Cancer Institute, National Institutes of Health
Zhiya YuNational Cancer Institute, National Institutes of Health
Matthew B BoxerDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Jeffrey A KieferTranslational Genomics Research Institute
John A CoplandMayo Clinic
John A CoplandMayo Clinic
Robert C SmallridgeMayo Clinic
Robert C SmallridgeMayo Clinic
Robert C SmallridgeMayo Clinic
Robert C SmallridgeMayo Clinic
Zhuyin LiDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Zhuyin LiDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Min ShenDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Min ShenDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Electron KebebewNational Cancer Institute, National Institutes of Health
Electron KebebewNational Cancer Institute, National Institutes of Health
  • 1 - 30

Datasets

Release 1.2